Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
136
0
4

Year Published

2017
2017
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 109 publications
(144 citation statements)
references
References 97 publications
4
136
0
4
Order By: Relevance
“…It should be considered that the previous ICE study included subjects untreated with IVIG for 3 months prior to the study as compared with the PRIMA population of which half were untreated for 1 year, and PATH in which all subjects were pre‐treated. The response rate in treatment‐naïve subjects in the PRIMA study (46.7%) is in a similar range to the 55% INCAT response rate reported in treatment‐naïve subjects in the Cochrane review . A higher response rate was observed in pre‐treated subjects in our combined analysis; the Kuwabara et al study, where all subjects were IVIG pre‐treated, had a responder rate of 77.6% at Week 28 .…”
Section: Discussionsupporting
confidence: 82%
See 1 more Smart Citation
“…It should be considered that the previous ICE study included subjects untreated with IVIG for 3 months prior to the study as compared with the PRIMA population of which half were untreated for 1 year, and PATH in which all subjects were pre‐treated. The response rate in treatment‐naïve subjects in the PRIMA study (46.7%) is in a similar range to the 55% INCAT response rate reported in treatment‐naïve subjects in the Cochrane review . A higher response rate was observed in pre‐treated subjects in our combined analysis; the Kuwabara et al study, where all subjects were IVIG pre‐treated, had a responder rate of 77.6% at Week 28 .…”
Section: Discussionsupporting
confidence: 82%
“…Immunoglobulins (Igs), corticosteroids, and plasma exchange are considered as first‐line therapies . Intravenous Ig (IVIG) was suggested to be efficacious vs plasma exchange, prednisolone, and placebo in several small trials, and in a Cochrane review, including five of these trials, totaling 235 subjects (mainly treatment‐naïve) provided evidence that more subjects had improvements in disability with IVIG treatment (44%) vs placebo (18%) . Included in these five studies was the landmark immune globulin intravenous CIDP efficacy (ICE) trial, which reported efficacy in a randomized trial considered large for the CIDP disease area .…”
Section: Introductionmentioning
confidence: 99%
“…The criteria from the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/ DOI: 10.1159/000494291 PNS) from 2010 are based on a combination of clinical and electrodiagnostic characteristics and are currently the most widely accepted criteria to confirm the diagnosis of CIDP [4]. Proven effective treatments for CIDP are immunoglobulins, corticosteroids and plasmapheresis [8].…”
Section: Introductionmentioning
confidence: 99%
“…Most patients with CIDP require maintenance treatment for years or even decades [8]. CIDP is therefore a disabling disorder with a considerable impact on patients and patient-related health care costs [9][10][11][12][13][14].…”
Section: Introductionmentioning
confidence: 99%
“…Unlike myasthenic crisis or GBS, corticosteroids, IVIG, and PLEX are all considered first‐line therapies for patients with classical CIDP. Multiple studies demonstrate the benefits of these treatments with a typical 50–70% respondent rate to initial therapy . There are only a few case reports of ICPI irAE CIDP .…”
Section: Disease Specific Considerationsmentioning
confidence: 99%